T1	Participants 540 567	Twenty male, white patients
T2	Participants 663 736	a double-blind, randomized, placebo-controlled, fourfold cross-over study
T3	Participants 1256 1275	combination therapy
T4	Participants 1368 1383	enalapril alone
T5	Participants 1429 1445	eprosartan alone
T6	Participants 1629 1644	enalapril alone
T7	Participants 1679 1695	eprosartan alone
T8	Participants 1864 1875	combination
T9	Participants 1901 1916	eprosartan phas
T10	Participants 1956 1971	enalapril phase
T11	Participants 2041 2116	active treatment with the most prominent reduction in the combination phase
T12	Participants 2255 2297	eprosartan with half the dose of enalapril
